NSE Listed · Pharmaceuticals

Supriya Lifescience Ltd. (SUPRIYA)

₹695.8▼ -19.99%

Vol 19.67 LAvg 1W 4.90 LAvg 1M 2.30 L

₹545.5₹1085

NSE ↗BSE ↗www.supriyalifescience.com ↗

₹695.8▼ 11.69% · 1Y

2025-11-07

2026-11-06

20-day avg volume: 2.3L shares

Key ratios

Market cap (Cr)5600

Price695.8

Prev close869.64

52W high1085

52W low545.5

Volume19.67 L

Avg Vol (1W)4.90 L

Avg Vol (1M)2.30 L

P/E28.18

EPS24.69

Book value148.82

Face value2

P/B4.68

Div Yield %14

ROE %17.46

ROA %14.62

Revenue (Cr)₹828 Cr

Profit margin %22.74

Debt/Equity0

Quarterly results

Jun 2026Rev ₹190 Cr · PAT ₹24 Cr

Mar 2026Rev ₹277 Cr · PAT ₹74 Cr

Dec 2025Rev ₹206 Cr · PAT ₹50 Cr

Sept 2025Rev ₹200 Cr · PAT ₹50 Cr

Jun 2025Rev ₹145 Cr · PAT ₹35 Cr

Mar 2025Rev ₹184 Cr · PAT ₹50 Cr

Annual results

Mar 2026Rev ₹839 Cr · PAT ₹209 Cr

Mar 2025Rev ₹706 Cr · PAT ₹188 Cr

Mar 2024Rev ₹581 Cr · PAT ₹119 Cr

Mar 2023Rev ₹470 Cr · PAT ₹90 Cr

Mar 2022Rev ₹538 Cr · PAT ₹152 Cr

Mar 2021Rev ₹396 Cr · PAT ₹124 Cr

Balance sheet

Mar 2026Assets ₹1,357 Cr · Equity ₹1,198 Cr

Mar 2025Assets ₹1,117 Cr · Equity ₹997 Cr

Mar 2024Assets ₹921 Cr · Equity ₹815 Cr

Mar 2023Assets ₹820 Cr · Equity ₹699 Cr

Mar 2022Assets ₹735 Cr · Equity ₹616 Cr

Mar 2021Assets ₹445 Cr · Equity ₹269 Cr

Shareholding

Promoters68.3%

Institutions11.91%

Public19.79%

About

Pharmaceuticals · Pharmaceuticals - Indian - Bulk Drugs & Formln

Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, antihypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, it is developing drugs in the areas of anti-depressant, anti-inflammatory, contrast media, hormones, antibiotic, smoking cessation, anti-diabetic/obesity, anti-ataxia, decongestant, veterinary API, anti-cancer, allogeneic hematopoietic stem cell transplantation, and anti-migraine. Supriya Lifescience Limited was founded in 1987 and is headquartered in Mumbai, India.

www.supriyalifescience.com ↗

Efficiency & working capital

ROCE %23%

Interest coverage100.2

Dividend payout %—

Debtor days88 d

Inventory days64 d

Payable days44 d

Cash conversion cycle107 d

Working capital days151 d

Shareholding details · 2026-09-30

Promoter %68.3%

FII %6.4%

DII %5.5%

Public %19.8%

Promoter pledge %0%

No. of shareholders78,561

Shareholding pattern

	Dec 23	Mar 24	Jun 24	Sept 24	Dec 24	Mar 25	Jun 25	Sept 25	Dec 25	Mar 26	Jun 26	Sept 26
Promoters	68.3%	68.3%	68.3%	68.3%	68.3%	68.3%	68.3%	68.3%	68.3%	68.3%	68.3%	68.3%
FIIs	4.6%	5.4%	4.9%	6%	6.5%	7.2%	6.8%	5.5%	5.2%	5.2%	6.2%	6.4%
DIIs	3.8%	5.3%	5.5%	5.4%	4.9%	4.3%	4.9%	5.2%	5%	5.7%	5.3%	5.5%
Public	23.3%	21%	21.3%	20.2%	20.3%	20.3%	20.1%	21%	21.5%	20.8%	20.2%	19.8%
Pledge	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Shareholders	95,929	87,980	89,621	85,328	89,394	91,051	91,928	87,912	85,099	81,161	82,082	78,561

Returns history

202603ROE — · ROCE — · ROA —

Major shareholders (>1%)

Satish Waman Wagh67.6%

Cohesion Mk Best Ideas Sub-trust3.2%

Aditya Birla Sun Life Insurance Company Limited2.2%

Smita Satish Wagh0.4%

Saloni Satish Wagh0.1%

Shivani Satish Wagh0.1%

Arun Waman Wagh0%

Satish Waman Wagh Partner Representing Supriyapharmaceuticals0%

Board of directors

Satish Waman WaghChairman

Smita Satish WaghE D & Wholetime Director

Saloni Satish WaghE D & Wholetime Director

Shivani Satish WaghE D & Wholetime Director

Balasaheb G. SawantE D & Wholetime Director

Neelam Yashpal AroraIndependent Non Exe. Director

Ganapati D YadavIndependent Non Exe. Director

Sunil Subhash BhagwatIndependent Non Exe. Director

Prachi SatheCompany Sec. & Compli. Officer

MANISH ISHWARLAL PANCHALAdditional Independent Director

Kothandaraman HariAdditional Independent Director

Corporate actions

forthcoming · 2026-09-04Dividend

dividend · 2026-09-04₹1 (50%)

forthcoming · 2026-08-13Board Meetings

dividend · 2025-09-04₹1 (50%)

Capital structure (₹ Cr)

Face value₹2

Authorised35

Issued16

Paid-up16

Company info

Incorporated2008

ChairmanSatish Waman Wagh

AuditorKakaria & Associates LLP

📍 207/208 Udyog Bhavan, Sonawala Road Goregaon (East), Mumbai, Maharashtra, 400063

Educational only — not investment advice.